$0.444
+0.003 (+0.61%)終値時点
IBO のニュース
IBO のイベント
Impact BioMedical Reveals U.S. Patent Issuance for 3F
Impact Biomedical announces that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled "Composition and Method of Controlling Infectious Diseases with Functional Fragrances," developed within IBO's 3F technology platform. This patent relates to composition and method for controlling infectious diseases. It includes compositions and formulations of constituents found in plants and fragrances produced by plants, with potential application as an antibacterial or antiviral agent. This patent will expire on December 7, 2038. This expands Impact Biomedical's 3F patent estate which includes insect repellent compositions and anti-microbial applications in the United States and other countries
Impact BioMedical, Dr Ashleys enter strategic merger agreement
Dr Ashleys Limited and Impact BioMedical announced the execution of a merger and share exchange agreement on June 21, 2025 to enter into a strategic merger transaction. Upon closing of the Transaction, Dr. Ashleys will acquire Impact BioMedical through a reverse merger that will result in a newly formed combined entity traded on the NYSE American under the name "Dr Ashleys Limited." Under the terms of the Merger Agreement, a merger subsidiary incorporated in Nevada as a PubCo subsidiary will merge with and into Impact BioMedical, with Impact BioMedical being the surviving entity. Simultaneous with or immediately following the merger, PubCo shall acquire all of the issued and outstanding shares of Dr Ashleys Bio Labs Limited, a Cayman Islands exempted company holding all shares of Dr. Ashleys. As a result of the Transaction, Impact BioMedical and Dr. Ashleys shall become wholly-owned subsidiaries of PubCo. Upon closing, the PubCo will be operated by the management team of Dr Ashleys, with a new Board of Directors to be assembled by Dr Ashleys. The Boards of Directors of both Dr Ashleys and Impact BioMedical have unanimously approved the proposed Transaction, subject to, among other things, approval by Impact BioMedical's shareholders, and satisfaction of the conditions provided in the Merger Agreement, including regulatory approvals and other customary closing conditions, including an effective registration statement on Form F-4 or S-4 in connection with the proposed Transaction being declared effective by the U.S. Securities and Exchange Commission and the approval of listing applications with the New York Stock Exchange.
Impact BioMedical announces acquisition of Celios in $1.15M equity transaction
Impact BioMedical announced the acquisition of Celios in a strategic, all equity transaction valued at approximately $1.15M. This acquisition aligns with Impact Biomedical's focused roll-up strategy, expanding its portfolio with solutions that will generate immediate revenue while reinforcing its commitment to human health and wellness. The company said, "Celios brings advanced air purification capability, featuring design, system, and method patents issued in the U.S. and other countries with exclusivity through 2043. It delivers "virtually clean room" air quality through novel U.S. manufactured filter technology, which is highly effective, yet portable with an easy-to-use design. With the acquisition of Celios, Impact Biomedical takes a substantial step forward in its mission to deliver best-in-class healthcare and wellness solutions. The addition of Celios technology complements Impact Biomedical's existing suite of innovations, reinforcing its ambition in human health and wellness."
DSS announces sale of Celios to Impact BioMedical
DSS (DSS) announced the sale of its Celios air purification asset to Impact BioMedical (IBO) in a strategic, all-equity transaction valued at approximately $1.15M. This divestiture aligns with DSS' ongoing strategy to optimize its portfolio and concentrate on core growth areas. "The sale of Celios to Impact BioMedical represents another step in our strategic efforts to streamline our holdings and focus on our core business objectives," said Jason Grady, CEO of DSS, Inc. "Impact BioMedical is well-positioned to leverage Celios' innovative air purification technology, and we believe this transition will maximize the platform's potential while allowing DSS to continue to focus into areas with stronger long-term synergies."
Impact BioMedical CEO says 'well-positioned' to drive long-term value
Impact BioMedical announced that Frank Heuszel, Chairman and CEO of Impact BioMedical Inc., issued a letter to Impact BioMedical shareholders, which read in part, "We closed our first quarter as a publicly traded company and wanted to address all current and future stakeholders highlighting our recent achievements, our appreciation for your support, and some additional insights into why we are excited for the future and continued success of Impact BioMedical Inc! We are pleased to share this update on the heels of significant achievements after having just filed our quarterly report for the third quarter of 2024... On September 16, 2024, IBO successfully launched its Initial Public Offering, raising $4.5 million in capital. The 1.5 million shares included in the IPO are freely tradable on the NYSE. The remaining 10 million shares issued and outstanding are restricted from trading until March 2025. This key milestone for the company provides us with resources to accelerate our research and development initiatives, expand our market presence, and enhance shareholder value. Following the IPO, our company was officially listed on the NYSE American under the ticker IBO...For the third quarter of 2024, IBO reported net income of $4,241,000, reflecting our ability to drive value. September 30, 2024 year-to-date net income stands at $2,363,000. IBO has also made considerable progress in enhancing our financial stability and shareholder value. From June 30, 2024, to September 30, 2024, our shareholder equity increased from $28.26 million to $34.56 million, marking a $6.3 million increase. This represents growth of approximately $.54 per share. Additionally, as of the end of the third quarter, the company's cash position was approximately $2.66 million, positioning us well for investment in strategic initiatives and operational needs...As part of our ongoing efforts to optimize our capital structure, we successfully restructured our long-term debt during the third quarter. This restructuring improves our financial flexibility, enabling repayment of the debt with company equity for 24 months allowing the Company to conserve cash, which will further enhance our ability to invest in growth and innovation...We are also actively collaborating with strategic partners to advance the development and funding of key assets. These partnerships are critical to driving the commercialization and monetization of our cutting-edge technologies...Moreover, we continue our pursuit of new products that have the potential to expand our portfolio and enhance the company's value proposition. Our teams are focused on advancing these promising initiatives in the pipeline...The third quarter of 2024 was a period of sturdy growth and strategic progress for Impact BioMedical Inc. With the successful IPO, strong financial performance, improved balance sheet, and continued investment in innovation, we are well-positioned to drive long-term value for our shareholders. We remain committed to executing our strategic goals and look forward to updating you on our progress as it applies to all four of our core platform technologies. To further this point, we are hosting a LIVE WEBINAR on November 20th at 4:30 pm eastern time where you will have the opportunity to hear directly from myself as well as Mark Suseck and Todd Macko, where we will provide a full update on the company including our anticipated milestones and plans for the rest of 2024 and beyond."
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。